SCHEMBL21597600

SCHEMBL21597600

O=C(O)c1c(NC(=O)C2CC2)sc2c1CCCO2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.49
HSD17B10 Q99714 2/20 0.47
KDM4E B2RXH2 2/20 0.47
MAPT P10636 2/20 0.47
CXCR2 P25025 1/20 0.44
FABP4 P15090 2/20 0.42
FABP5 Q01469 2/20 0.42
ALDH1A1 P00352 4/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
GAA P10253 1/20 0.41
PTPN1 P18031 4/20 0.41
PTPRC P08575 2/20 0.41
PTPN2 P17706 2/20 0.41
PTPRB P23467 2/20 0.41
PTPRE P23469 2/20 0.41
PTPN6 P29350 1/20 0.41
KMT2A Q03164 2/20 0.40
NOD1 Q9Y239 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27415543 0.86 KDM4E (0.47) FLT3HSD17B10KDM4EMAPTCXCR2
SCHEMBL21597699 0.82 ALDH1A1 (0.57) HSD17B10KDM4EMAPTCXCR2ALDH1A1
SCHEMBL3914277 0.78 FLT3 (0.77) FLT3HSD17B10KDM4EMAPTALDH1A1
SCHEMBL21597756 0.75 FLT3 (0.50) FLT3HSD17B10KDM4EMAPTALDH1A1
SCHEMBL5453432 0.75 PTPN1 (0.71) FLT3HSD17B10KDM4EMAPTPTPN1
SCHEMBL21603874 0.74 KDM4E (0.50) FLT3HSD17B10KDM4EMAPTCXCR2
SCHEMBL7540375 0.73 PTPN1 (0.62) PTPN1PTPRCPTPN2PTPRBPTPRE
SCHEMBL5741223 0.73 FLT3 (0.69) FLT3HSD17B10KDM4EMAPTALDH1A1
SCHEMBL3760411 0.72 PTPN1 (0.67) FLT3HSD17B10KDM4EMAPTPTPN1
Water SCHEMBL21597714 0.71 KDM4E (0.47) FLT3HSD17B10KDM4EMAPTCXCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
EP-3810606-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2021-04-28 EP disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 FLT3 3722/4885HSD17B10 1200/4885KDM4E 3965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.